Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 3Pancreatic Neoplasms 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Stomach Neoplasms 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 358Fluorouracil 94Oxaliplatin 81Capecitabine 74130-nm albumin-bound paclitaxel 71Albumin-Bound Paclitaxel 70Radiotherapy 67Leucovorin 58Irinotecan 49Erlotinib Hydrochloride 47Cisplatin 44Bevacizumab 31pembrolizumab 30Radiosurgery 30Docetaxel 26Taxes 24Nivolumab 24Cetuximab 24Pancreaticoduodenectomy 20Drug Therapy 17folfirinox 16Cyclophosphamide 16Radiation 15Ipilimumab 13Endoscopic Ultrasound-Guided Fine Needle Aspiration 13Surgical Procedures, Operative 12Sorafenib 12Paclitaxel 12Neoadjuvant Therapy 12irinotecan sucrosofate 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Pancreatic Neoplasms × genexol-PM × Clear all
NCT00882973 2017-05-05

Trial to Determine the Maximum Tolerated Dose of Genexol-PM Plus Gemcitabine and Evaluate Efficacy and Safety of Genexol-PM Regimens in Subjects With Advanced Pancreatic Cancer

Samyang Biopharmaceuticals Corporation

Phase 1 Completed
18 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT00111904 2011-12-14

Paclitaxel in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

National Cancer Institute (NCI)

Phase 2 Completed
43 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡